LZM-005 / Livzon Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LZM-005 / Livzon Pharma
CTR20191921: LZM005-Phase Ib clinical trial

Completed
1b
20
China
LZM-005 - Livzon Pharma
Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd.
HER2-positive metastatic or locally advanced breast cancer
 
 
CTR20170991: A single-center, open-label, dose-escalation phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of LZM005 injection in patients with advanced breast cancer

Recruiting
1
16
China
LZM-005 - Livzon Pharma
Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd.
Breast cancer;Oncology
 
 

Download Options